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A B S T R A C T
Patients undergoing multivisceral transplantation are particularly susceptible to post-operative
infections due to immunosuppression and the inclusion of bowel in the transplanted graft. These
patients typically receive broad-spectrum antimicrobial and antifungal agents as prophylaxis and
treatment. However, evidence for this is limited due to the small number of patients undergoing the
procedure. We present a case of occult disseminated invasive aspergillosis infection in a patient who
underwent multivisceral transplantation.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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A 53-year-old female, diagnosed with Crohn’s disease in 1979,
had a colonic perforation with peritonitis and was left with short
bowel syndrome following surgery in 1989. She was dependent on
parenteral nutrition but developed intestinal failure associated
liver disease and underwent a multivisceral transplant (stomach,
liver, pancreas, small bowel and colon) in December 2011. She was
discharged home after 5 months.
Fifteen months post-transplantation she was readmitted with
diarrhoea and nausea due to small and large bowel rejection. She
failed to respond to increasing immunosuppression (methylpred-
nisolone, tacrolimus, mycophenolate mofetil and inﬂiximab) and
so her transplanted colon was resected to facilitate reduction in her
immunosuppression. She developed sepsis and was temporarily
neutropenic, so received broad-spectrum antibacterial agents
and ﬂuconazole (due to an anaphylactic reaction to liposomal
amphotericin B).* Corresponding author at: Department of Gastroenterology Box 133, Adden-
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3.0/).She developed multiorgan failure including a microangiopathic
haemolytic anaemia requiring plasma exchange. Magnetic reso-
nance imaging of her brain showed multiple small ischaemic
lesions in the cortex and white matter bilaterally and a larger
lesion in the right cerebellum, which was either haemorrhagic or
an abscess (Fig. 1). A transthoracic echocardiogram showed no
vegetations.
Two days later a serum galactomannan was performed which
was positive (1.18 [normal range < 0.5], and sputum grew
Aspergillus fumigatus; ﬂuconazole was changed to posaconazole.
Despite this the patient continued to deteriorate and died. Post
mortem conﬁrmed aspergillosis involving the brain, lungs and
myocardium (Fig. 2).
Discussion
Invasive aspergillosis occurs in 1–15% of solid organ transplant
recipients [1]. There are three case reports of invasive aspergillosis
infection following multivisceral transplantation [2–4]. It should
be considered in profoundly immunosuppressed individuals even
after a signiﬁcant time post-transplant.
We believe that mould-active prophylaxis should be considered
in this group of patients as studies of the use of antigen tests (e.g.
galactomannan) and nucleic acid ampliﬁcation tests in solid organe under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
Fig. 1. MRI brain showing lesion in right cerebellum suggestive of haemorrhage or
an abscess.
Fig. 2. Cardiac myocardium specimen showing fungal hyphae.
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this population. In haematology patients, studies suggest normal
neutrophil counts [6] and mould-active prophylaxis can reduce
the sensitivity of this test [6,7]. It has been reported that they are
less sensitive in other solid organ transplant recipients than in the
stem cell transplant population [1]. The choice of antifungal can be
difﬁcult as some patients are intolerant to amphotericin B
(including lipid formulations) and triazoles interact with many
other agents.Our patient demonstrated disseminated invasive aspergillosis
infection more than 18 months post transplantation. This is later
than has previously been reported in this patient group [2–4]. In
addition, it was difﬁcult to diagnose despite using galactomannan
testing, imaging and a low threshold for therapy.
Transplant teams (including microbiology, infectious diseases
and radiology) must be aware of the risk of mould infections in all
patients undergoing multivisceral transplant and ensure adequate
therapy is administered. Early diagnosis is also essential to
improve prognosis.
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